Comera Life Sciences (NASDAQ:CMRA – Get Free Report) and Leap Therapeutics (NASDAQ:LPTX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.
Insider and Institutional Ownership
30.5% of Leap Therapeutics shares are owned by institutional investors. 8.9% of Comera Life Sciences shares are owned by insiders. Comparatively, 4.3% of Leap Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Comera Life Sciences and Leap Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Comera Life Sciences | 0 | 0 | 0 | 0 | 0.00 |
| Leap Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
Profitability
This table compares Comera Life Sciences and Leap Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Comera Life Sciences | N/A | N/A | N/A |
| Leap Therapeutics | N/A | -247.44% | -146.51% |
Volatility and Risk
Comera Life Sciences has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of -0.06, suggesting that its share price is 106% less volatile than the S&P 500.
Earnings and Valuation
This table compares Comera Life Sciences and Leap Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Comera Life Sciences | $1.00 million | 0.00 | -$18.00 million | ($0.49) | N/A |
| Leap Therapeutics | N/A | N/A | -$67.56 million | ($1.22) | -1.68 |
Comera Life Sciences has higher revenue and earnings than Leap Therapeutics. Leap Therapeutics is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Comera Life Sciences beats Leap Therapeutics on 9 of the 11 factors compared between the two stocks.
About Comera Life Sciences
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
About Leap Therapeutics
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Comera Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Comera Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
